Rosalind Advisors Inc. Has $2.68 Million Holdings in COMPASS Pathways plc (NASDAQ:CMPS)

Rosalind Advisors Inc. trimmed its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 9.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 707,625 shares of the company's stock after selling 73,798 shares during the quarter. COMPASS Pathways makes up about 1.3% of Rosalind Advisors Inc.'s portfolio, making the stock its 20th largest holding. Rosalind Advisors Inc. owned about 1.03% of COMPASS Pathways worth $2,675,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also added to or reduced their stakes in CMPS. China Universal Asset Management Co. Ltd. bought a new stake in shares of COMPASS Pathways during the fourth quarter worth about $41,000. Wealthfront Advisers LLC bought a new stake in COMPASS Pathways during the 4th quarter worth approximately $43,000. Flagship Harbor Advisors LLC acquired a new position in COMPASS Pathways in the 4th quarter valued at approximately $43,000. Conservest Capital Advisors Inc. increased its position in COMPASS Pathways by 28.9% in the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock valued at $51,000 after acquiring an additional 3,000 shares during the period. Finally, Essential Planning LLC. bought a new position in shares of COMPASS Pathways during the fourth quarter valued at $70,000. Institutional investors own 46.19% of the company's stock.

COMPASS Pathways Trading Up 2.2 %

CMPS stock traded up $0.09 during mid-day trading on Friday, reaching $4.19. The company's stock had a trading volume of 630,372 shares, compared to its average volume of 798,868. COMPASS Pathways plc has a 12 month low of $2.49 and a 12 month high of $9.63. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The business's 50 day moving average price is $3.34 and its 200 day moving average price is $4.11. The company has a market cap of $388.30 million, a price-to-earnings ratio of -1.90 and a beta of 2.34.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, equities research analysts predict that COMPASS Pathways plc will post -2.33 EPS for the current year.

Analyst Upgrades and Downgrades

CMPS has been the subject of a number of recent research reports. Stifel Nicolaus started coverage on COMPASS Pathways in a report on Thursday, February 27th. They issued a "buy" rating and a $11.00 price objective for the company. Canaccord Genuity Group decreased their price target on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, February 28th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Cantor Fitzgerald reissued an "overweight" rating on shares of COMPASS Pathways in a research report on Friday, March 28th. Finally, HC Wainwright restated a "buy" rating and issued a $45.00 price target on shares of COMPASS Pathways in a research report on Tuesday, March 4th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $20.20.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.